skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

3 Total results for product and free and sample content found

Scrip

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

By Jung Won Shin 27 Nov 2020

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Topic Diabetes Obesity

View article

Scrip

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

By Emily Hayes 27 Nov 2020

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Topic Obesity Clinical Trials

View article

Datamonitor Healthcare

The majority of overweight and obese patients do not receive pharmacotherapy

03 Nov 2016

The US obesity market is expected to increase in value from $533m in 2016 to $1.2bn in 2026, at a compound annual growth rate of 8.0%. Growth will be driven by increased use of branded pharmacological therapies to treat obesity, as well as the rising incidence of the disease.

Topic Obesity Research wire

View opinion

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now